I Have APOE4. What Do I Do Now?

Patient Guide · APOE ε4 · Risk Reduction

I Have APOE4. What Do I Do Now?

By Brian Paquette, DO, MPH

A practical guide to what the evidence actually supports after an APOE ε4 result — graded honestly, including the trials that came back negative. Most of what matters is unglamorous, and nearly all of it is already available to you.

The Moment You Saw the Result

Perhaps you ordered a consumer genetic test out of curiosity. Perhaps Alzheimer’s disease runs in your family and you wanted to know. Either way, you opened a report and read something like APOE ε3/ε4, or APOE ε4/ε4, and the question that follows is always the same.

I am a neurologist. I am also an APOE ε4 carrier. What follows is what I tell patients, and what I have decided for myself — with the evidence behind each recommendation stated plainly, including where it is weaker than the headlines suggest.

The headline: APOE ε4 is a risk factor, not a diagnosis. It shifts probabilities. It does not determine outcomes, and it does not tell you when — or whether — you will develop cognitive symptoms.

First: What Your Result Actually Means

You inherit one copy of the APOE gene from each parent. Three common versions circulate in human populations: ε2, ε3, and ε4. The ε3 allele is by far the most common. The ε2 allele is generally associated with lower Alzheimer’s risk; ε4 with higher risk.

One copy — ε3/ε4 — raises risk relative to ε3/ε3, but leaves a great deal unresolved. Many single-copy carriers live long lives without dementia.

Two copies — ε4/ε4 — is a different situation, and it deserves accurate language rather than a frightening multiplier. In a pooled analysis of 3,297 autopsy cases and 10,039 individuals with biomarker data, Fortea and colleagues found that nearly all ε4 homozygotes showed Alzheimer’s pathology, with abnormal biomarkers appearing from around age 55 and amyloid abnormality nearly universal in cerebrospinal fluid by 65. Median age at symptom onset was 65.1 years, within a narrower prediction interval than for ε3 homozygotes (Fortea et al., Nature Medicine, 2024, DOI).

A distinction that is routinely lost online: developing Alzheimer’s biology in the brain is not the same event as developing clinical dementia. The gap between the two is measured in years to decades, and it is influenced by age, vascular health, education, cognitive reserve, other genes, and factors we have not yet identified.

Two Reactions That Are Both Wrong

The first is fatalism: I am going to get this anyway, so nothing I do matters. The second is its mirror image: if I find the right diet and the right supplements, I can guarantee I will not.

Neither survives contact with the data. Nothing currently available guarantees prevention. But the 2024 report of the Lancet standing Commission identified 14 potentially modifiable risk factors across the life course which, in aggregate at the population level, are associated with roughly 45% of dementia cases (Livingston et al., Lancet, 2024, DOI).

That 45% figure is a theoretical population ceiling under complete elimination of every risk factor. It is not a personal risk reduction, and anyone quoting it to you as one is misusing it.

Does Lifestyle Work Differently If You Carry ε4?

This is the question carriers ask most, and the honest answer is more interesting than the marketing answer.

Two large randomized trials have tested this directly. In the FINGER trial’s prespecified APOE subgroup analysis (1,109 participants, 362 ε4 carriers), the difference in intervention effect between carriers and non-carriers was 0.023 (95% CI −0.021 to 0.067) — not statistically significant (Solomon et al., JAMA Neurology, 2018, DOI). In US POINTER (n = 2,111), benefit from the structured multidomain program was consistent across carriers and non-carriers, with P = .95 for the genotype-by-treatment interaction (Baker et al., JAMA, 2025, DOI).

The correct statement: lifestyle benefit in ε4 carriers is preserved, not amplified. Your genotype does not blunt the effect — but no trial supports telling you that these measures help you more than they help a non-carrier. What is defensible is this: because your baseline absolute risk is higher, the same proportional benefit returns a larger absolute benefit to you. That is reason enough.

Start With Vascular and Metabolic Health

If I had to choose one domain, it would be this one. What is good for the heart is broadly good for the brain, and the relevant measurements are inexpensive and already part of routine care: blood pressure, LDL-C, ApoB, lipoprotein(a), fasting glucose, HbA1c, and weight trend.

APOE encodes a lipid-transport protein, and the ε4 allele is associated with higher LDL cholesterol on average — though not in every carrier. Whether ε4 independently raises coronary risk, however, is genuinely contested — and you will meet confident claims in both directions.

A 2004 meta-analysis of 48 studies found ε4 carriers had a 42% higher coronary heart disease risk than ε3/ε3 (OR 1.42, 95% credible interval 1.26–1.61), and concluded that ε4 is a significant risk factor for coronary disease (Song et al., Annals of Internal Medicine, 2004, DOI). A 2007 meta-analysis was larger — 82 studies of lipid levels in 86,067 healthy participants and 121 studies of coronary outcomes in 37,850 cases and 82,727 controls — and was built specifically to correct the small-study bias its authors argued had dominated earlier reviews. It found a much smaller effect: OR 1.06 (95% CI 0.99–1.13), a confidence interval that crosses unity (Bennet et al., JAMA, 2007, DOI).

The two also disagree about ε2, which the 2007 analysis found protective (OR 0.80, 0.70–0.90) and the 2004 analysis found null (OR 0.98, 0.66–1.46). The larger, bias-corrected estimate points to a smaller independent coronary effect than the earlier literature implied — but the evidence is genuinely mixed, and ε4 should not be called coronary-neutral.

The practical conclusion is the same either way: treat your lipids because lipids matter. Your genotype neither exempts you from cardiovascular risk nor delivers a verdict on it.

On blood pressure, the evidence deserves precision. SPRINT MIND randomized 9,361 hypertensive adults to a systolic target below 120 versus below 140 mm Hg. Intensive control did not significantly reduce adjudicated probable dementia (HR 0.83, 95% CI 0.67–1.04) — the trial stopped early and was likely underpowered for that endpoint. It did significantly reduce mild cognitive impairment (HR 0.81, 95% CI 0.69–0.95) (Williamson et al., JAMA, 2019, DOI).

Hypertension is silent. Do not rely on how you feel. Know the number, and know it in midlife, because that is when the vascular contribution to later cognitive decline is being written.

Exercise, Consistently

There is no APOE4-specific workout. The targets are the standard ones: 150–300 minutes per week of moderate-intensity aerobic activity (or 75–150 minutes of vigorous activity, or an equivalent mix), plus muscle-strengthening activity on two or more days per week (Piercy et al., JAMA, 2018, DOI). For older adults, add balance training.

The structural evidence is real. In a randomized trial of 120 older adults, one year of moderate aerobic training increased anterior hippocampal volume by about 2% — reversing roughly one to two years of age-related loss — with parallel improvement in spatial memory, while the stretching control group lost volume (Erickson et al., PNAS, 2011, DOI).

A hard workout does not neutralize an otherwise sedentary day. Walk. Take stairs. Move after meals. Break up long sitting. And choose the program you will still be doing in ten years over the one that looks optimal on paper.

Eat for Vascular Health — and Know What the Diet Trials Showed

There is no scientifically established “APOE4 diet.” Online you will find confident advocacy for ketogenic patterns, very-low-fat patterns, fasting protocols, and elaborate individualized programs. The confidence is not matched by the trial evidence.

The most rigorous test of the MIND pattern is instructive. A three-year randomized trial in 604 cognitively unimpaired adults with a family history of dementia compared the MIND diet with mild caloric restriction against a control diet with mild caloric restriction. Both groups improved, and the between-group difference was not significant (0.035 standardized units, 95% CI −0.022 to 0.092; P = 0.23). MRI measures did not differ either (Barnes et al., New England Journal of Medicine, 2023, DOI).

That trial was negative on its primary endpoint. It does not make a Mediterranean- or MIND-style pattern a bad choice — the observational literature remains favorable, both arms improved, and the achieved dietary separation between arms was modest. But it does mean the honest recommendation is: eat a minimally processed, plant-forward, fish-inclusive pattern because it is good for your vasculature and metabolic health, not because a randomized trial has shown it protects cognition. It has not.

One practical point specific to ε4 carriers: given APOE‘s role in lipid handling, if a dietary change drives your LDL-C or ApoB substantially upward, that finding deserves attention rather than dismissal on the grounds that the diet is otherwise considered healthy. Measure your response instead of assuming it.

Protect Your Sleep — and Screen for Apnea

Seven to nine hours is a reasonable adult target, but duration is not the whole story. Obstructive sleep apnea is common, frequently undiagnosed, and treatable — which makes it one of the highest-yield things to look for.

In a prospective study of 298 older women with baseline polysomnography, sleep-disordered breathing was associated with subsequent mild cognitive impairment or dementia (adjusted OR 1.85, 95% CI 1.11–3.08); the signal tracked with measures of intermittent hypoxia rather than sleep fragmentation or total sleep time (Yaffe et al., JAMA, 2011, DOI).

Note the limit: this is observational, in an all-female cohort of advanced age. And here the study designs split sharply, which is worth understanding because it explains the conflicting claims you will meet.

Observational data look encouraging. Among 53,321 Medicare beneficiaries aged 65 and over with diagnosed obstructive sleep apnea, positive airway pressure treatment was associated with lower odds of an incident Alzheimer’s diagnosis (OR 0.78, 95% CI 0.69–0.89), and evidence of adherent use with lower odds still (OR 0.65, 95% CI 0.56–0.76) (Dunietz et al., Sleep, 2021, DOI).

The randomized trials show much less. A meta-analysis of 11 randomized trials in 923 patients found significant improvement on a single measure — Trail Making Test part B (SMD −0.93, 95% CI −1.60 to −0.25; p = 0.007), consistent with a short-term gain in cognitive flexibility — and no effect on processing speed, executive function, or working memory. In most of those trials CPAP had been running three months or less (Durtette et al., Sleep Medicine, 2024, DOI). A systematic review of 38 studies reporting outcomes beyond one year found no clinically significant effect of CPAP on cognitive function, and rated the strength of evidence low throughout (Balk et al., Journal of Clinical Sleep Medicine, 2024, DOI).

Both patterns can be true at once. Observational cohorts cannot separate the effect of treatment from the characteristics of people who seek it out and stay with it — that same review found that adding non-randomized studies turned an apparently null mortality effect into an apparently protective one, which is a clean illustration of the problem. And short trials cannot detect a process that unfolds over decades. No randomized trial has shown that treating sleep apnea prevents dementia, and none has used incident dementia as an endpoint.

None of which changes what you should do. Treat sleep apnea because it is treatable, and because untreated apnea harms your cardiovascular health, your daytime function, and your quality of life now. If you snore loudly, stop breathing during sleep, wake unrefreshed, or are excessively sleepy during the day, raise it with your physician — there are good reasons to treat apnea regardless of what it does to your dementia risk.

Hearing, Alcohol, Smoking, and Your Head

Hearing. Hearing loss features prominently in the Lancet Commission’s list, and the randomized evidence is more nuanced than the coverage suggested. ACHIEVE randomized 977 adults aged 70–84 with untreated hearing loss to hearing aids plus audiological counseling or to a health-education control. Over three years, the primary analysis was null (difference 0.002, 95% CI −0.077 to 0.081; p = 0.96). A prespecified sensitivity analysis found the effect differed between the two enrolled cohorts (p = 0.010), with apparent benefit confined to the higher-risk ARIC participants (Lin et al., Lancet, 2023, DOI). Treat hearing loss — communication and social participation are worth protecting in their own right — but do not be told the cognitive case is settled.

Alcohol. Older observational work sometimes suggested a protective effect of modest drinking; that literature has not held up well. At the heavy end the signal is unambiguous. In a French nationwide cohort of over 31 million hospital discharges, alcohol use disorders were the strongest modifiable risk factor for dementia onset (adjusted HR 3.34 in women, 3.36 in men) and were present in a majority of early-onset cases (Schwarzinger et al., Lancet Public Health, 2018, DOI). Do not start drinking for your brain. If you drink, less is safer than more.

Smoking. Quitting remains among the highest-value single actions available to anyone, for cerebrovascular, cardiovascular, and general health reasons. No supplement offsets continued tobacco exposure.

Head injury. Traumatic brain injury is on the modifiable list. Helmets, seatbelts, serious attention to fall prevention as you age, and avoiding unnecessary repetitive head impacts are mundane compared with biomarkers and genetics — and considerably more consequential than most of what is marketed as brain optimization.

Stay Engaged — and Note What Actually Worked in the Trials

Education, cognitively demanding activity, and social connection all contribute to what researchers call cognitive reserve. The operative variables appear to be novelty and difficulty, not time spent on familiar puzzles.

There is a subtler lesson in US POINTER worth carrying with you. Both arms of that trial improved. The structured, supervised, socially embedded program beat the self-guided version by 0.029 SD per year (95% CI 0.008–0.050; P = .008) — a small difference, but one suggesting that structure, accountability, and being part of a group are themselves active ingredients, not merely delivery mechanisms. If you are going to change how you live, do it with other people and with some scaffolding.

What About Supplements?

This is usually the first question, and the evidence is far less impressive than the marketing.

Omega-3 fatty acids are the most scientifically interesting of the commonly marketed options, and they still illustrate the problem. In a randomized, double-blind, placebo-controlled trial of 402 participants with mild-to-moderate Alzheimer’s disease, 2 g/day of algal DHA for 18 months produced no benefit on cognitive or functional decline (ADAS-cog change P = .41; CDR sum of boxes P = .68) and no effect on brain atrophy (Quinn et al., JAMA, 2010, DOI). That trial tested treatment of established disease, not prevention in healthy carriers — a real distinction — but it is a sobering result for a compound often presented as established.

One detail in that trial matters specifically to you. In a subgroup analysis specified in the statistical plan before the study began, the DHA signal — such as it was — appeared only in APOE ε4 non-carriers. Among them, ADAS-cog scores rose 6.23 points (95% CI 4.08–8.38, n = 61) on DHA versus 10.11 points (95% CI 7.12–13.10, n = 48) on placebo (P = .03), with a parallel difference on the MMSE. Among ε4 carriers there was no treatment effect on any outcome measure.

The trial’s authors were careful about this and so should you be. The testing was not adjusted for multiple comparisons, and the apparent benefit did not appear on the CDR sum of boxes, activities of daily living, neuropsychiatric symptoms, or brain atrophy — which, as they wrote, weakens the case that it is clinically meaningful. They called for independent replication before anyone infers a real effect.

The direction is still worth knowing, because it is not isolated. The same genotype split appears with medium-chain triglycerides and exogenous ketones, where cognitive benefit has likewise been confined to ε4-negative participants. If you are being sold omega-3 on the strength of Alzheimer’s trial data, the genotype that produced the signal is not yours.

Supplements have a legitimate role in correcting documented deficiencies and in managing specific medical conditions. No supplement has been shown to prevent Alzheimer’s disease in an otherwise healthy APOE ε4 carrier. Before committing several hundred dollars a month, spend that attention on blood pressure, lipids, glucose, fitness, sleep, hearing, tobacco, and human connection. Those recommendations are duller. Their evidence base is far stronger.

Should You Get Blood Biomarker Testing?

Blood-based markers — particularly phosphorylated tau 217 — have genuinely changed Alzheimer’s evaluation. In 1,767 participants with cognitive symptoms across five cohorts, an automated plasma p-tau217 assay detected Alzheimer’s pathology with areas under the curve of 0.93–0.96, with 85% accuracy in primary care and 89–91% in specialty settings (Palmqvist et al., Nature Medicine, 2025, DOI).

One finding from that study is worth knowing if you carry ε4, because the opposite is often asserted: test accuracy was unaffected by APOE genotype, as well as by chronic kidney disease, diabetes, sex, and cognitive stage. Accuracy fell only in participants aged 80 and over. Your genotype does not require a different cutoff.

Note also who was studied: people with cognitive symptoms. That is the population in which these performance figures apply. Whether an entirely asymptomatic carrier should be tested is a different question, and the answer is not automatically yes. A test should answer a clinical question and change what you do. Testing without symptoms carries psychological, insurance, and practical consequences that deserve to be weighed before, not after. If you have cognitive symptoms, that is a different situation and warrants a proper evaluation.

Evidence Strength at a Glance

Action Evidence for cognition What the best trial showed
Structured multidomain program MODERATE US POINTER: +0.029 SD/year vs self-guided (P = .008); same benefit for ε4 carriers (P = .95)
Aerobic exercise MODERATE +2% anterior hippocampal volume and improved spatial memory at 1 year (n = 120)
Blood pressure control MODERATE (MCI)
NULL (dementia)
SPRINT MIND: MCI HR 0.81 (0.69–0.95); probable dementia HR 0.83 (0.67–1.04), not significant
Avoiding heavy alcohol use MODERATE
(observational)
Alcohol use disorder: adjusted HR ≈3.3 for dementia onset; strongest modifiable factor identified
Identifying sleep apnea MODERATE (risk)
WEAK (outcome)
Sleep-disordered breathing → MCI/dementia OR 1.85 (1.11–3.08). PAP treatment associated with lower incident AD (OR 0.78) observationally; RCTs show only short-term, domain-limited gains
Mediterranean / MIND pattern WEAK MIND RCT negative on primary endpoint at 3 years (P = 0.23); observational data favorable
Hearing aids WEAK ACHIEVE: null overall (p = 0.96); benefit only in the higher-risk enrolled cohort
Omega-3 / DHA supplements NO BENEFIT IN ε4 CARRIERS 2 g/day DHA for 18 months: no effect on cognition, function, or atrophy in mild–moderate AD. Prespecified subgroup benefit confined to ε4 non-carriers (P = .03, unadjusted for multiplicity)

Your Practical Checklist

1. Understand your genotype. Know what it predicts and, more importantly, what it does not.

2. Know your blood pressure. Measured, not estimated from how you feel.

3. Measure and manage cardiometabolic risk. LDL-C, ApoB, lipoprotein(a) at least once, HbA1c, weight trend.

4. Exercise on a schedule you will keep. 150–300 minutes moderate aerobic per week, plus strength training twice weekly.

5. Eat a minimally processed, plant-forward pattern — and recheck your lipids after any major dietary change.

6. Take sleep seriously and get apnea evaluated if any symptom suggests it.

7. Do not smoke, and keep alcohol low. Both are among the clearest signals in the literature.

8. Get your hearing tested and use aids if they are recommended.

9. Protect your head. Helmets, seatbelts, fall prevention.

10. Stay socially and intellectually engaged — ideally in something structured and shared, which is what the trials actually tested.

11. Treat supplements as supplements. Correct deficiencies; do not buy prevention.

12. Discuss biomarker and cognitive testing with a clinician who knows this field, rather than ordering everything available.

13. Establish a baseline and follow trends across the measures above. The objective is sustained risk reduction over decades, not perfection this quarter.

Do Not Let Your Genotype Take Over Your Life

This may be the most important paragraph here.

Learning that you carry genetic risk for a disease you have watched take someone you love can reorganize how you think about the future. It can also become consuming. Every forgotten name acquires weight. Every misplaced set of keys becomes evidence. Every headline demands to be read.

That is not a good way to spend decades of healthy life. If the result is causing persistent anxiety, low mood, or preoccupation that interferes with your days, that is worth raising with your physician — it is a common and treatable response to genetic risk information, not a personal failing.

Exercise because it is good for your brain — and because climbing something with your family is worth doing. Eat well because your metabolic health matters — and still enjoy dinner with people you love. Protect your sleep. Learn difficult things. Keep your friendships in repair.

The bottom line: You cannot change the alleles you inherited. You can identify the health factors associated with cognitive aging, address the ones that are modifiable, follow the research as it matures, and revise as better evidence arrives. Know your risk. Act on what you control. Then get on with living.

Limitations of This Guidance

  • No lifestyle trial has used incident dementia as a primary endpoint. FINGER and US POINTER report cognitive composite scores over two years. These are surrogate outcomes.
  • Effect sizes are modest. The POINTER between-group difference of 0.029 SD per year is statistically robust and clinically small. Both arms improved.
  • Observational data overstate benefit. Prodromal neurodegeneration reduces activity, diet quality, and social engagement years before diagnosis, which inflates apparent effect sizes in cohort studies.
  • The ε4-specific interventional literature is thin. Two trials with prespecified APOE subgroups is not a large evidence base, and neither was powered as a genotype-stratified prevention trial.
  • Subgroup findings are fragile. The genotype-stratified DHA result comes from one subgroup of one negative trial, was not corrected for multiple comparisons, and has not been replicated. It is a caution, not a conclusion.
  • Dose and timing are undefined. Optimal exercise intensity, dietary composition, and the age at which intervention matters most are not established by trial data.
  • This is educational content, not individualized medical advice. Your age, family history, comorbidities, and medications all change how this applies to you.

References

  1. Fortea J, Pegueroles J, Alcolea D, et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease. Nat Med. 2024;30(5):1284–1291. doi:10.1038/s41591-024-02931-w
  2. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572–628. doi:10.1016/S0140-6736(24)01296-0
  3. Solomon A, Turunen H, Ngandu T, et al. Effect of the apolipoprotein E genotype on cognitive change during a multidomain lifestyle intervention: a subgroup analysis of a randomized clinical trial. JAMA Neurol. 2018;75(4):462–470. doi:10.1001/jamaneurol.2017.4365
  4. Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA. 2025;334(8):681–691. doi:10.1001/jama.2025.12923
  5. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141(2):137–147. doi:10.7326/0003-4819-141-2-200407200-00013
  6. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298(11):1300–1311. doi:10.1001/jama.298.11.1300
  7. Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553–561. doi:10.1001/jama.2018.21442
  8. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020–2028. doi:10.1001/jama.2018.14854
  9. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017–3022. doi:10.1073/pnas.1015950108
  10. Barnes LL, Dhana K, Liu X, et al. Trial of the MIND diet for prevention of cognitive decline in older persons. N Engl J Med. 2023;389(7):602–611. doi:10.1056/NEJMoa2302368
  11. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306(6):613–619. doi:10.1001/jama.2011.1115
  12. Dunietz GL, Chervin RD, Burke JF, Conceicao AS, Braley TJ. Obstructive sleep apnea treatment and dementia risk in older adults. Sleep. 2021;44(9):zsab076. doi:10.1093/sleep/zsab076
  13. Durtette A, Dargent B, Gierski F, et al. Impact of continuous positive airway pressure on cognitive functions in adult patients with obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med. 2024;123:7–21. doi:10.1016/j.sleep.2024.08.019
  14. Balk EM, Adam GP, Cao W, Bhuma MR, D’Ambrosio C, Trikalinos TA. Long-term effects on clinical event, mental health, and related outcomes of CPAP for obstructive sleep apnea: a systematic review. J Clin Sleep Med. 2024;20(6):895–909. doi:10.5664/jcsm.11030
  15. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023;402(10404):786–797. doi:10.1016/S0140-6736(23)01406-X
  16. Schwarzinger M, Pollock BG, Hasan OSM, Dufouil C, Rehm J. Contribution of alcohol use disorders to the burden of dementia in France 2008–13: a nationwide retrospective cohort study. Lancet Public Health. 2018;3(3):e124–e132. doi:10.1016/S2468-2667(18)30022-7
  17. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903–1911. doi:10.1001/jama.2010.1510
  18. Palmqvist S, Warmenhoven N, Anastasi F, et al. Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform. Nat Med. 2025;31(6):2036–2043. doi:10.1038/s41591-025-03622-w

EDITORIAL NOTE: All 18 citations independently verified against the primary source record. Brian Paquette, DO, MPH is a double board-certified neurologist and pain medicine physician, a former US Naval Flight Surgeon, and an APOE ε4 carrier. APOE4 Insights accepts no industry sponsorship and has no supplement affiliations. Educational content only; not a substitute for individual clinical judgement.

Just learned you carry APOE4?

Get the free physician’s guide Your First 30 Days After an APOE4 Result, plus one evidence update a month.

No spam. Unsubscribe anytime.

Just learned you carry APOE4?

Get the free physician’s guide Your First 30 Days After an APOE4 Result, plus one evidence update a month.

No spam. Unsubscribe anytime.

Similar Posts